DCC4860 |
Spmtrien |
Novel isosteric charge-deficient spermine analogue |
|
DCC4861 |
spongiacidin C |
USP7 inhibitor from the marine sponge Stylissa massa |
|
DCC4862 |
Spongosine |
Pivotal intercellular signal transmitter |
|
DCC4863 |
Spop-in-6lc |
Novel SPOP inhibitor, suppressing the viability and inhibiting the colony formation of ccRCC cell lines driven by cytoplasmic SPOP |
|
DCC4864 |
Spt-in-1 |
Novel potent serine palmitoyl transferase (SPT) inhibitor |
|
DCC4865 |
Sptssb-binder-18 |
Novel potent and selective binder of small subunit B of the serine palmitoyltransferase complex (SPTSSB) |
|
DCC4866 |
Spu-106 |
Novel specific PAK4 inhibitor, effectively inhibiting the invasion of SGC7901 cells without cytotoxicity, regulating the PAK4/LIMK1/cofilin and PAK4/SCG10 signaling pathways |
|
DCC4867 |
Sr-01000634273-1 |
Novel inhibitor of the in vivo aggregation of |
|
DCC4868 |
Sr10098 |
Novel NR4A nuclear receptor modulator |
|
DCC4869 |
Sr10658 |
Novel NR4A nuclear receptor modulator |
|
DCC4870 |
Sr142948a |
Selective neurotensin antagonist |
|
DCC4871 |
Sr-17398 Hydrochloride |
Novel Unc-51-Like Kinase 1 (ULK1) |
|
DCC4872 |
Sr2067 |
Novel partial agonist of PPARgamma |
|
DCC4873 |
Sr24237 |
Novel NR4A nuclear receptor modulator |
|
DCC4874 |
Sr-3737 |
Potent inhibitor of both JNK3 and p38 |
|
DCC4875 |
Sr-4326 |
Novel Inhibitor of c-Jun N-terminal Kinase 3 (JNK3) |
|
DCC4876 |
Sr-43845 |
Novel renin inhibitor |
|
DCC4877 |
Sr-58611a |
The first selective β3 adrenergic agonist, showing to possess a profile of antidepressant activity in rodents |
|
DCC4878 |
Sr8185 |
Novel Selective TBK1/IKK dual inhibitor with anticancer potency |
|
DCC4879 |
Srctide |
Peptide substrate for many protein kinases, such as Blk, BTK, cKit, EPHA1, EPHB2, EPHB3, ERBB4, FAK, Flt3, IGF-1R, ITK, Lck, MET, MUSK, Ret, Src, TIE2, TrkB, VEGF-R1 (Flt-1) and VEGF-R2 (KDR) |
|
DCC4880 |
Srebp-in-dhg |
Novel inhibitor of sterol regulatory element-binding protein (SREBP), impairing the SREBP activity by inhibiting glucose transporters and thereby activating AMP-activated protein kinase (AMPK) |
|
DCC4881 |
Sri-22138 |
Novel mixed μ opioid receptor (MOR) agonist and δ/κ opioid receptor (DOR/KOR) antagonist |
|
DCC4882 |
Sri-29132 |
Highly blood-brain barrier permeant, potent, and selective for LRRK2 kinase activity, being effective in attenuating pro-inflammatory responses in macrophages and rescuing neurite retraction phenotypes in neurons. |
|
DCC4883 |
Sri-31040 |
Potent DAT allosteric modulator, partially inhibiting DAT uptake without altering DAT-mediated reverse transport and with minimal inhibition of DAT binding |
|
DCC4884 |
Sri-35241 |
Novel inhibitor of thrombospondin 1 activation of TGF-β, blocking TGF-β activation (pIC50 = 8.12 nM) and has a plasma half life of 1.8 h (iv) |
|
DCC4885 |
Sri-36160 |
Novel potent inhibitor of Wn/ß-catenin signaling in cancer cells |
|
DCC4886 |
Sri-37683 |
Novel GLUT inhibitor, preferentially inhibiting the growth of GBM cells with minimal toxicity to non-neoplastic astrocytes and neurons, also inhibiting glucose uptake and decrease the glycolytic capacity and glycolytic reserve capacity of GBM patient-deri |
|
DCC4887 |
Sri-37684 |
Novel GLUT inhibitor, preferentially inhibiting the growth of GBM cells with minimal toxicity to non-neoplastic astrocytes and neurons, also inhibiting glucose uptake and decrease the glycolytic capacity and glycolytic reserve capacity of GBM patient-deri |
|
DCC4888 |
Sri-39067 |
Novel MOR agonist/DOR antagonist that produced systemically active potent antinociceptive activity in tail-flick assay in mice |
|
DCC4889 |
Srt3025 |
Novel Sirtuin1 Activator, Down-Regulating Sclerostin and Rescuing Ovariectomy-Induced Bone Loss |
|